Obesity-Diabetes Drugs Market Analysis by Meglitinides and Oral Administration through 2034

<p>The global <strong>obesity-diabetes drugs market</strong> is estimated to be worth USD 56,739.0 million in 2024 and is projected to reach a value of USD 97,567.47 million by 2034, expanding at a CAGR of 5.6% over the assessment period.</p><table> <tbody> <tr> <th scope='row'>Attributes</th> <td>Description</td> </tr> <tr> <th scope='row'>Estimated Global Obesity-Diabetes Drugs Market Size (2024E)</th> <td>USD 56,739.0 million</td> </tr> <tr> <th scope='row'>Projected Global Obesity-Diabetes Drugs Market Value (2034F)</th> <td>USD 97,567.4 million</td> </tr> <tr> <th scope='row'>Value-based CAGR (2024 to 2034)</th> <td>5.6%</td> </tr> </tbody></table><p>Country-wise Insights</p><table> <tbody> <tr> <th scope='row'>Countries</th> <td>CAGR 2024 to 2034</td> </tr> <tr> <th scope='row'>The United States</th> <td>4.7%</td> </tr> <tr> <th scope='row'>China</th> <td>5.7%</td> </tr> <tr> <th scope='row'>Germany</th> <td>3.8%</td> </tr> <tr> <th scope='row'>The United Kingdom</th> <td>4.0%</td> </tr> <tr> <th scope='row'>India</th> <td>6.4%</td> </tr> </tbody></table><p>Category-Wise Insights</p><table> <tbody> <tr> <th scope='row'>Segment</th> <td>Drug Therapy (Therapy Type)</td> </tr> <tr> <th scope='row'>Value Share (2024)</th> <td>55.9%</td> </tr> </tbody></table><table> <tbody> <tr> <th scope='row'>Segment</th> <td>Institutional Sales (Sale Channel)</td> </tr> <tr> <th scope='row'>Value Share (2024)</th> <td>39.7%</td> </tr> </tbody></table>

<p>全球肥胖-糖尿病药物市场预计在2024年将达到567.39亿美元的价值，并预计到2034年将达到975.6747亿美元，在整个评估期内以5.6%的复合年增长率（CAGR）扩张。</p><table> <tbody> <tr> <th scope='row'>属性</th> <td>描述</td> </tr> <tr> <th scope='row'>2024年预计全球肥胖-糖尿病药物市场规模</th> <td>567.39亿美元</td> </tr> <tr> <th scope='row'>2034年预计全球肥胖-糖尿病药物市场价值</th> <td>975.674亿美元</td> </tr> <tr> <th scope='row'>基于价值的CAGR（2024年至2034年）</th> <td>5.6%</td> </tr> </tbody></table><p>按国家洞察</p><table> <tbody> <tr> <th scope='row'>国家</th> <td>2024年至2034年CAGR</td> </tr> <tr> <th scope='row'>美国</th> <td>4.7%</td> </tr> <tr> <th scope='row'>中国</th> <td>5.7%</td> </tr> <tr> <th scope='row'>德国</th> <td>3.8%</td> </tr> <tr> <th scope='row'>英国</th> <td>4.0%</td> </tr> <tr> <th scope='row'>印度</th> <td>6.4%</td> </tr> </tbody></table><p>按类别洞察</p><table> <tbody> <tr> <th scope='row'>细分</th> <td>药物治疗（治疗类型）</td> </tr> <tr> <th scope='row'>价值份额（2024年）</th> <td>55.9%</td> </tr> </tbody></table><table> <tbody> <tr> <th scope='row'>细分</th> <td>机构销售（销售渠道）</td> </tr> <tr> <th scope='row'>价值份额（2024年）</th> <td>39.7%</td> </tr> </tbody></table>